Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney Disease

Published: 2025-03-27 07:08:36 ET RGLS

March 27 (Reuters) - Regulus Therapeutics Inc:

* REGULUS THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF ITS PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL OF FARABURSEN (RGLS8429) FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

* REGULUS THERAPEUTICS INC -POSITIVE TOPLINE DATA FROM FOURTH COHORT OF PATIENTS

* REGULUS THERAPEUTICS-PATIENTS RECEIVING 300 MG FARABURSEN DEMONSTRATED MEAN HALTING OF HEIGHT-ADJUSTED TOTAL KIDNEY VOLUME GROWTH OVER 4 MONTHS

* REGULUS THERAPEUTICS INC -ON TRACK FOR INITIATION OF PHASE 3 SINGLE PIVOTAL TRIAL IN Q3 2025 Source text: Further company coverage: